What makes rheumatology billing different
Our rheumatology billing services are built around the infusion suite. Biologic drugs billed by the milligram, buy-and-bill inventory sitting on your shelf, prior authorization for nearly every biologic, and injection visits mixed with long-term office care make rheumatology one of the most financially exposed specialties to bill. Fastora's certified billing and coding professionals handle rheumatology claims as part of our wider medical billing services.
A single infusion claim can be worth many times an office visit, which means one coding or authorization error costs more here than in most specialties. We run eligibility and benefits checks before infusions and new biologic starts, confirming the drug benefit, the authorization status and the patient's cost share so neither the practice nor the patient is surprised.
Infusion billing: J-codes, administration and wastage
| Code | Descriptor (summary) | Billing note |
|---|---|---|
| 96365 | Therapeutic infusion, up to 1 hour | First hour; hydration codes have separate rules |
| 96366 | Therapeutic infusion, each additional hour | Add-on; time must reach the code thresholds |
| J1745 | Infliximab, 10 mg | Units equal total mg divided by 10 |
| J0129 | Abatacept, 10 mg | IV formulation for the infusion suite |
| J1602 | Golimumab for IV use, 1 mg | Weight-based dosing drives the units |
| 20610 | Arthrocentesis, aspiration or injection; major joint | Knee, hip, shoulder; 20600 small, 20605 medium |
| 76942 | Ultrasonic guidance for needle placement | Add-on to the injection code |
Drug units are the top audit target. Units must equal the administered dose divided by the code's descriptor amount, and any discarded drug from a single-dose vial is reported with the JW modifier, or JZ when nothing was discarded. We reconcile the dose, the vial sizes and the waste on every infusion claim, because a unit error on a biologic is an expensive error.
Buy-and-bill and the drug inventory behind the claim
Buy-and-bill means the practice purchases the biologic, stores it, administers it and then bills the payer for the drug plus the administration. The drug cost sits on your shelf before a dollar is collected, so slow or denied drug claims strain cash flow directly.
Reimbursement is generally tied to published pricing benchmarks, not to your invoice, which leaves a spread the practice has to manage. We keep drug claims clean on the first pass, track drug receivables separately from office receivables, and follow up on high-balance drug claims by payer and age so inventory costs do not sit in AR for months.
Prior authorization and step therapy for biologics
Nearly every biologic needs prior authorization, and most plans apply step therapy: the patient must try and fail a lower-cost option before the requested drug is approved. Requests need the diagnosis, disease activity measures, prior therapies with dates and outcomes, and the dosing plan.
Our prior authorization team builds the request from the chart, tracks step therapy history across plans when patients switch coverage, and calendars reauthorization dates so maintenance infusions do not lapse mid-course.
Joint injections and ultrasound guidance
In-office joint injections are coded by joint size: small, medium and major joints each have their own code, and ultrasound guidance is reported as an add-on when imaging is used for needle placement. Bilateral injections need the side modifiers or bilateral reporting the payer expects.
An office evaluation on the same day as an injection needs modifier 25 and a separately documented problem beyond the injection itself. Routine rechecks that only lead to a planned injection series do not qualify, and payers watch this combination in rheumatology closely.
Common rheumatology denials and how we prevent them
| Denial | Typical cause | Prevention step |
|---|---|---|
| Drug units denied | Units do not match dose and vial math | Dose, vials and waste reconciled before submission |
| Wastage rejected | JW or JZ missing on single-dose vial drugs | Wastage modifiers applied per payer rule |
| Biologic not authorized | Step therapy not documented in the request | Therapy history built into every request |
| Injection bundled | E/M and injection on the same day without support | Modifier 25 only with a separately documented problem |
| Reauthorization lapsed | Approval expired mid maintenance course | Reauthorization dates calendared and tracked |
Infusion denials get same-week attention. A denied drug claim holds up the most expensive part of the practice's revenue, so we work these by payer and cause instead of letting them age with routine AR.
How Fastora supports rheumatology practices
Fastora works inside your existing EHR/PM system under the user access you grant, with no software to install and no hidden setup fees. You get a dedicated account contact, transparent dashboards, monthly performance reporting and a monthly review call.
Fees are quoted after a free assessment, so we can see your infusion volume, biologic mix and authorization patterns first. Start with a free billing assessment and we will show you where claims are slowing down before you commit to anything.
Infusion billing for rheumatology practices
Infusion medical billing is the revenue engine of most rheumatology practices — and the hardest part to get right. Drug (J-code) and administration codes have to match the administered dose, wastage rules have to be documented, and the prior authorization has to cover the specific drug, not just the diagnosis. Our infusion billing services reconcile ordered versus administered doses, verify benefits against the medical benefit before the infusion and follow up on the underpaid drug claims that hide inside otherwise clean A/R.
Rheumatology medical billing done well treats the infusion suite like its own revenue center: scheduled authorizations, dose reconciliation and payment checks on every claim. Related services: prior authorization service, eligibility verification, medical billing services.